Identification of tumor autoantibody biomarker candidates for colon cancer using high density peptide microarrays

Regina Soldo, Silvia Schönthaler (Vortragende:r), Peter Hettegger, Jasmin Huber, Markus Degeorgi, Walter Pulverer, Christa Nöhammer, Stefanie Brezina, Gernot Leeb, Andrea Gsur, Andreas Weinhäusel

Publikation: Posterpräsentation ohne Beitrag in TagungsbandPosterpräsentation ohne Eintrag in Tagungsband


Colorectal cancer represents one of the most common cancers worldwide. Novel minimal-invasive diagnostic assays are currently developed for early diagnosis of cancer. We are focusing on the analysis of tumor autoantibodies, which occur in many tumor patients due to altered protein expression of the tumor cells, presenting then tumor-associated antigens (TAAs) to the immune system.
Tumor autoantibody profiling has been conducted on AIT’s 16k protein-microarray for different cancer indications (colon, lung, breast, and lung cancer). Based on the profiling results, we have designed a high-density peptide array presenting 179,000 peptides deduced from 2,090 candidate antigenic-protein-markers and 6,000 peptides derived from frequently mutated genes in cancer (COSMIC). IgG was purified from plasma samples of a cohort, comprising 24 colorectal cancer patients, 24 polyps, and 24 cancer-free controls. The reactivity of the IgG of the patient cohort to the peptides on the microarray was tested and analyzed. A high number of differentially reactive peptides could be identified between patient groups and 360 peptides were selected for further validation using Luminex®-technology, where 190 clinical samples were tested. Moreover, the reactivity of 66 mutated peptide sequences, deduced from the COSMIC database, was compared to the wild-type sequence.
Although a high number of differentially reactive peptides could be retrieved from the high-density peptide microarray, during validation, when analytical platform was changed, only a classification success with AUC values ranging between 0.68 – 0.75 could be achieved. Platform transfer in biomarker screening studies is a critical step and requires elaborated protocols for wet lab and statistical analysis.

High density peptide arrays enable efficient screening of antibodies directed against specific amino acid sequences derived from whole antigens or in cancer specifically mutated proteins. We are developing our technology further to also achieve best performance in validation using targeted bead arrays and peptide-microarrays.
PublikationsstatusVeröffentlicht - 28 Apr. 2023
VeranstaltungCCC-TRIO 2023: Translational Oncology & Immuno-Oncology + Onkologischer Pflegefachtag - Vienna, Österreich
Dauer: 27 Apr. 202328 Apr. 2023


KonferenzCCC-TRIO 2023

Research Field

  • Molecular Diagnostics


Untersuchen Sie die Forschungsthemen von „Identification of tumor autoantibody biomarker candidates for colon cancer using high density peptide microarrays“. Zusammen bilden sie einen einzigartigen Fingerprint.

Diese Publikation zitieren